Flora Peyvandi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1160337/publications.pdf

Version: 2024-02-01

663 papers	33,075 citations	6613 79 h-index	6471 157 g-index
685 all docs	685 docs citations	685 times ranked	36588 citing authors

#	Article	IF	Citations
1	Evaluation of procoagulant imbalance in Cushingâ€™s syndrome after short- and long-term remission of disease. Journal of Endocrinological Investigation, 2022, 45, 9-16.	3.3	3
2	A homozygous duplication of the <I>FGG</i> exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family. Haematologica, 2022, 107, 1064-1071.	3.5	3
3	Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clinical Pharmacokinetics, 2022, 61, 505-513.	3.5	2
4	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
5	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines, 2022, 10, 249.	3.2	16
6	The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients. Haemophilia, 2022, , .	2.1	1
7	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
8	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
9	Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain and Therapy, 2022, 11, 1-15.	3.2	4
10	Obituary for Stefano Duga (1967â€“2021): A life for science. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	0
11	Prognostic value of copeptin and midâ€regional proadrenomedullin in COVIDâ€19â€hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	3.4	13
12	Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A. Haemophilia, 2022, 28, 270-277.	2.1	1
13	Worldwide SARS-CoV-2 haplotype distribution in early pandemic. PLoS ONE, 2022, 17, e0263705.	2.5	2
14	Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia. Cells, 2022, 11, 1148.	4.1	7
15	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
16	Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Human Gene Therapy, 2022, 33, 432-441.	2.7	37
17	Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry. Journal of Clinical Medicine, 2022, 11, 1969.	2.4	6
18	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12

#	Article	IF	Citations
19	Phenotypic and genetic characterizations of the Milan cohort of von Willebrand disease type 2. Blood Advances, 2022, 6, 4031-4040.	5.2	5
20	Impact of a commercially available <scp>DOAC</scp> absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban. International Journal of Laboratory Hematology, 2022, 44, .	1.3	0
21	Lombardy diagnostic and therapeutic network of thrombotic microangiopathy. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	2
22	Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients. Microorganisms, 2022, 10, 1191.	3.6	6
23	External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019. European Journal of Internal Medicine, 2022, 102, 63-71.	2.2	3
24	Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2022, 6, 5463-5466.	5.2	2
25	ISTH Biennial Impact Report: Looking back and looking forward. Journal of Thrombosis and Haemostasis, 2022, 20, 1515-1517.	3.8	0
26	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
27	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
28	The ADAMTS13â€von Willebrand factor axis in COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 513-521.	3.8	176
29	Hemostasis in pregnant women with COVIDâ€19. International Journal of Gynecology and Obstetrics, 2021, 152, 268-269.	2.3	6
30	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. Journal of Allergy and Clinical Immunology, 2021, 147, 561-566.e4.	2.9	90
31	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thrombosis Research, 2021, 197, 132-137.	1.7	13
32	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	2.5	1
33	Efficacy and safety of fibrinogen concentrate for onâ€demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency. Haemophilia, 2021, 27, 283-292.	2.1	13
34	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	3.8	14
35	Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy. Infectious Diseases, 2021, 53, 226-229.	2.8	6
36	X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. European Journal of Human Genetics, 2021, 29, 241-249.	2.8	17

#	Article	IF	Citations
37	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
38	Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?. Journal of Ultrasound, 2021, 24, 165-173.	1.3	16
39	Hemostatic alterations in COVID-19. Haematologica, 2021, 106, 1472-1475.	3.5	34
40	Relationship between thrombin generation parameters and prothrombin fragment 1Â+Â2 plasma levels. International Journal of Laboratory Hematology, 2021, 43, e248-e251.	1.3	3
41	Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. Radiologia Medica, 2021, 126, 722-728.	7.7	31
42	Anti-TNF-Î± Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1901-1908.	1.9	5
43	Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma. Platelets, 2021, , 1-3.	2.3	1
44	Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Internal and Emergency Medicine, 2021, 16, 1223-1229.	2.0	31
45	Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. Journal of Autoimmunity, 2021, 117, 102595.	6.5	44
46	Characterization of the neutralizing antiâ€emicizumab antibody in a patient with hemophilia A and inhibitor. Journal of Thrombosis and Haemostasis, 2021, 19, 711-718.	3.8	19
47	Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein. International Journal of Molecular Sciences, 2021, 22, 2001.	4.1	1
48	Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1087-1096.	3.4	9
49	Healthâ€related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitorsâ€"A nonâ€interventional study. Haemophilia, 2021, 27, 398-407.	2.1	15
50	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9
51	Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia. Thrombosis Research, 2021, 199, 110-118.	1.7	7
52	Von Willebrand disease type 2N: An update. Journal of Thrombosis and Haemostasis, 2021, 19, 909-916.	3.8	14
53	IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2021, 32, 1227-1235.	6.1	9
54	Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Reviews, 2021, 50, 100833.	5.7	6

#	Article	IF	Citations
55	Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study. Journal of Thrombosis and Thrombolysis, 2021, 52, 224-231.	2.1	8
56	Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. Advances in Therapy, 2021, 38, 2709-2716.	2.9	2
57	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39
58	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
59	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	2.1	1
60	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine, 2021, 47, 899-902.	8.2	38
61	Adoption of emicizumab (HemlibraÂ®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia, 2021, 27, 736-743.	2.1	11
62	International Society on Thrombosis and Haemostasis: Present and future. Journal of Thrombosis and Haemostasis, 2021, 19, 1599-1601.	3.8	0
63	Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood, 2021, 137, 3127-3136.	1.4	18
64	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1699-1708.	2.3	1
65	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Haematologica, 2021, 106, 3021-3024.	3.5	8
66	Subclinical myopathic changes in COVID-19. Neurological Sciences, 2021, 42, 3973-3979.	1.9	13
67	Hemophilic arthropathy: Current knowledge and future perspectives. Journal of Thrombosis and Haemostasis, 2021, 19, 2112-2121.	3.8	84
68	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1883-1887.	3.8	59
69	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5.2	11
70	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. Thrombosis Research, 2021, 204, 32-39.	1.7	11
71	Comparison of adverse drug reactions among four COVIDâ€19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. Journal of Thrombosis and Haemostasis, 2021, 19, 2554-2558.	3.8	37
72	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. Thrombosis Update, 2021, 4, 100059.	0.9	6

#	Article	IF	Citations
73	Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Reviews, 2021, 49, 100828.	5.7	8
74	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	2.7	3
75	Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors. Vaccines, 2021, 9, 1011.	4.4	9
76	Delivery of AAVâ€based gene therapy through haemophilia centresâ€"A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
77	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatology, The, 2021, 3, e690-e697.	3.9	121
78	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Journal of Autoimmunity, 2021, 124, 102728.	6.5	5
79	Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 310-310.	3.8	1
80	Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease. Journal of Thrombosis and Haemostasis, 2021, 19, 96-106.	3.8	7
81	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	3.8	7
82	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 365-371.	2.3	11
83	Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS ONE, 2021, 16, e0258675.	2.5	6
84	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1660-e1672.	3.6	7
85	Von Willebrand disease combined with coagulation defects in Iran. Blood Transfusion, 2021, 19, 428-434.	0.4	0
86	Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood, 2021, 138, 3184-3184.	1.4	2
87	Which Level of Emicizumab Is Necessary for a Good Hemostasis?. Blood, 2021, 138, 4247-4247.	1.4	0
88	Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience. Blood, 2021, 138, 1038-1038.	1.4	0
89	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	1.4	0
90	Factor VIII Epitope Analysis Using a Random Peptide Phage-Display Library Approach in the Sippet Cohort. Blood, 2021, 138, 3176-3176.	1.4	0

#	Article	IF	Citations
91	Efficacy and Safety of Azathioprine during Remission of Immune-Mediated Thrombotic Thrombocytopenic Purpura. Blood, 2021, 138, 773-773.	1.4	7
92	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	1.4	0
93	Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro. Blood, 2021, 138, 3193-3193.	1.4	0
94	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine, 2021, 10, 5959.	2.4	9
95	Pulmonary tumour thrombotic microangiopathy in a young man: clinical and immunohistochemical characterisation of a rare complication of gastric signet-ring cell carcinoma. Blood Transfusion, 2021, 19, 506-509.	0.4	0
96	How we make an accurate diagnosis of von Willebrand disease. Thrombosis Research, 2020, 196, 579-589.	1.7	18
97	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
98	The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. Thrombosis Research, 2020, 187, 197-201.	1.7	11
99	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. Thrombosis Research, 2020, 185, 96-101.	1.7	12
100	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. Journal of Thrombosis and Thrombolysis, 2020, 49, 413-419.	2.1	2
101	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
102	Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. Journal of Thrombosis and Haemostasis, 2020, 18, 815-824.	3.8	24
103	High rate of sustained virological response with directâ€acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver International, 2020, 40, 1062-1068.	3.9	13
104	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3.8	188
105	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
106	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
107	How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood, 2020, 136, 2125-2132.	1.4	19
108	The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. Journal of Clinical Medicine, 2020, 9, 3379.	2.4	5

#	Article	IF	Citations
109	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	3.8	24
110	COVID-19 multidisciplinary high dependency unit: the Milan model. Respiratory Research, 2020, 21, 260.	3.6	22
111	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. Frontiers in Pediatrics, 2020, 8, 510.	1.9	4
112	European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 2020, 15, 219.	2.7	6
113	Complement activation in patients with COVID-19: AÂnovel therapeutic target. Journal of Allergy and Clinical Immunology, 2020, 146, 215-217.	2.9	210
114	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	3.8	20
115	Pulmonary embolism in a young pregnant woman with COVID-19. Thrombosis Research, 2020, 191, 36-37.	1.7	52
116	Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2020, 105, 1957-1962.	3.5	28
117	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
118	Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura. European Journal of Internal Medicine, 2020, 75, 79-83.	2.2	8
119	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	2.1	28
120	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	27.0	1,548
121	Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica, 2020, 105, 2038-2043.	3.5	21
122	Profiling the mutational landscape of coagulation factor V deficiency. Haematologica, 2020, 105, e180-e185.	3.5	10
123	Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 644-651.	2.3	14
124	A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut, 2020, 69, 1148-1149.	12.1	60
125	Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease. Haemophilia, 2020, 26, 298-305.	2.1	7
126	Laboratory testing in hemophilia: Impact of factor and nonâ€factor replacement therapy on coagulation assays. Journal of Thrombosis and Haemostasis, 2020, 18, 1242-1255.	3.8	32

#	Article	IF	Citations
127	Dramatic presentation of acquired thombotic thrombocytopenic purpura associated with COVID-19. Haematologica, 2020, 105, e540.	3.5	35
128	Romeo and Juliet: Revisited (at the time of COVID-19). European Journal of Internal Medicine, 2020, 81, 94.	2.2	0
129	Comparison of von Willebrand factor plateletâ€binding activity assays: ELISA overreads type 2B with loss of HMW multimers. Journal of Thrombosis and Haemostasis, 2020, 18, 2513-2523.	3.8	2
130	How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease. Blood, 2020, 136, 1125-1133.	1.4	17
131	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. Clinical Microbiology and Infection, 2020, 26, 1576-1578.	6.0	10
132	Procoagulant imbalance in patients with non-cirrhotic Chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis. Digestive and Liver Disease, 2020, 52, e1-e2.	0.9	0
133	Factor VIII/Protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score. Digestive and Liver Disease, 2020, 52, e13-e14.	0.9	0
134	Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. Lancet Haematology,the, 2020, 7, e320-e328.	4.6	15
135	Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3. Platelets, 2020, 31, 960-963.	2.3	3
136	Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease. Haematologica, 2020, 105, e365-e369.	3.5	9
137	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. Thrombosis Research, 2020, 190, 20-25.	1.7	4
138	Where do we stand with antithrombotic prophylaxis in patients with COVID-19?. Thrombosis Research, 2020, 191, 29.	1.7	14
139	Hypercoagulability of COVIDâ€19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 1738-1742.	3.8	1,070
140	An international registry of patients with plasminogen deficiency (HISTORY). Haematologica, 2020, 105, 554-561.	3.5	13
141	Immune Responses to Plasma-Derived Versus Recombinant FVIII Products. Frontiers in Immunology, 2020, 11, 591878.	4.8	9
142	Perceived well-being and mental health in haemophilia. Psychology, Health and Medicine, 2020, 25, 1062-1072.	2.4	10
143	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
144	Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Seminars in Thrombosis and Hemostasis, 2019, 45, 036-042.	2.7	15

#	Article	IF	Citations
145	International Society on Thrombosis and Haemostasis core curriculum project: Core competencies in laboratory thrombosis and hemostasis. Journal of Thrombosis and Haemostasis, 2019, 17, 1848-1859.	3.8	8
146	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
147	Realâ€life experience in switching to new extended halfâ€life products at European haemophilia centres. Haemophilia, 2019, 25, 946-952.	2.1	35
148	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver International, 2019, 39, 2309-2316.	3.9	8
149	Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Reply. Journal of Thrombosis and Haemostasis, 2019, 17, 1405-1406.	3.8	2
150	Burden of mild haemophilia A: Systematic literature review. Haemophilia, 2019, 25, 755-763.	2.1	22
151	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open, 2019, 03, e123-e131.	1.4	4
152	Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia, 2019, 25, 738-746.	2.1	57
153	Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register. Internal and Emergency Medicine, 2019, 14, 1347-1352.	2.0	1
154	60. FOUR YEARS EXPERIENCE OF PREIMPLANTATION GENETIC TESTING OF FOUR MONOGENIC DISORDERS (CYSTIC FIBROSIS, BETA-THALASSAEMIA, HEMOPHILIA A AND B). Reproductive BioMedicine Online, 2019, 39, e63-e64.	2.4	0
155	Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity. Thrombosis and Haemostasis, 2019, 119, 1767-1772.	3.4	37
156	Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. Journal of Thrombosis and Haemostasis, 2019, 17, 492-498.	3.8	1
157	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. Journal of Thrombosis and Thrombolysis, 2019, 48, 52-60.	2.1	8
158	Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia, 2019, 25, 521-526.	2.1	5
159	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Reviews, 2019, 38, 100572.	5.7	29
160	FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage. Journal of Hepatology, 2019, 70, e507.	3.7	0
161	Consensus statements on vaccination in patients with haemophiliaâ€"Results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia, 2019, 25, 656-667.	2.1	16
162	Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry. Thrombosis and Haemostasis, 2019, 119, 695-704.	3.4	41

#	Article	IF	Citations
163	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. Journal of the American Medical Directors Association, 2019, 20, 1313-1317.e9.	2.5	5
164	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Medical Principles and Practice, 2019, 28, 501-508.	2.4	5
165	Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study. BMC Cardiovascular Disorders, 2019, 19, 55.	1.7	2
166	Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects. Haematologica, 2019, 104, 2084-2090.	3.5	9
167	Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica, 2019, 104, e380-e382.	3.5	30
168	Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency. International Journal of Molecular Sciences, 2019, 20, 910.	4.1	5
169	Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2019, 17, 666-669.	3.8	4
170	Management of rare acquired bleeding disorders. Hematology American Society of Hematology Education Program, 2019, 2019, 80-87.	2.5	15
171	Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open, 2019, 9, e028012.	1.9	7
172	Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. Blood Advances, 2019, 3, 1670-1680.	5.2	18
173	Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil. Blood Advances, 2019, 3, 3432-3435.	5.2	5
174	Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia. Annals of Hematology, 2019, 98, 2847-2849.	1.8	7
175	Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. European Journal of Internal Medicine, 2019, 61, 54-61.	2.2	52
176	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. Thrombosis Research, 2019, 174, 84-87.	1.7	4
177	Treatment of rare factor deficiencies other than hemophilia. Blood, 2019, 133, 415-424.	1.4	92
178	Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus. Haemophilia, 2019, 25, e30-e32.	2.1	5
179	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
180	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625

#	Article	IF	Citations
181	Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. Journal of Thrombosis and Haemostasis, 2019, 17, 52-62.	3.8	46
182	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica, 2019, 104, 1268-1276.	3.5	5
183	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. Clinical Chemistry, 2019, 65, 254-262.	3.2	23
184	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood, 2019, 134, 4908-4908.	1.4	1
185	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372.	3.5	4
186	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. Blood, 2019, 134, 2365-2365.	1.4	2
187	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366.	1.4	2
188	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. Blood, 2019, 134, 1093-1093.	1.4	0
189	Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". Blood Transfusion, 2019, 17, 86.	0.4	0
190	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.4	18
191	Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 825-828.	2.5	3
192	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. Haematologica, 2018, 103, e138-e140.	3.5	4
193	Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 220-227.	2.3	20
194	Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. European Journal of Internal Medicine, 2018, 52, e12-e14.	2.2	8
195	Recombinant factorÂXIII Aâ€subunit in a patient with factorÂXIII deficiency and recurrent pregnancy loss. Journal of Thrombosis and Haemostasis, 2018, 16, 1052-1054.	3.8	2
196	â€œIn vitroâ€•correction of the severe factor V deficiencyâ€•related coagulopathy by a novel plasmaâ€derived factor V concentrate. Haemophilia, 2018, 24, 648-656.	2.1	18
197	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	3.8	23
198	Acquired Von Willebrand syndrome and response to desmopressin. Haemophilia, 2018, 24, e25-e28.	2.1	6

#	Article	IF	Citations
199	European principles of inhibitor management in patients with haemophilia. Orphanet Journal of Rare Diseases, 2018, 13, 66.	2.7	33
200	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 407-428.	2.3	5
201	Firstâ€year results of an expanded humanitarian aid programme for haemophilia in resourceâ€constrained countries. Haemophilia, 2018, 24, 229-235.	2.1	32
202	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs and Aging, 2018, 35, 365-373.	2.7	17
203	An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia. Internal and Emergency Medicine, 2018, 13, 1233-1238.	2.0	0
204	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica, 2018, 103, e315-e317.	3.5	34
205	Polypharmacy in older adults with severe haemophilia. Haemophilia, 2018, 24, e1-e3.	2.1	4
206	The ISTH Bleeding Assessment Tool and the risk of future bleeding. Journal of Thrombosis and Haemostasis, 2018, 16, 125-130.	3.8	32
207	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 808-814.	1.7	43
208	Factor <scp>XIII</scp> deficiency diagnosis: Challenges and tools. International Journal of Laboratory Hematology, 2018, 40, 3-11.	1.3	47
209	A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method. Haemophilia, 2018, 24, 156-161.	2.1	5
210	Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity. Haematologica, 2018, 103, 344-350.	3.5	33
211	Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2018, 16, 253-261.	3.8	33
212	Molecular investigation of 41 patients affected by coagulation factor <scp>XI</scp> deficiency. Haemophilia, 2018, 24, e50-e55.	2.1	6
213	Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion, 2018, 58, 413-422.	1.6	19
214	Timing and severity of inhibitor development in recombinant versus plasmaâ€derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 39-43.	3.8	39
215	Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia, 2018, 24, 57-62.	2.1	21
216	Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTemÂ® device. Thrombosis Research, 2018, 172, 139-141.	1.7	4

#	Article	IF	Citations
217	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 2018, 118, 1729-1742.	3.4	24
218	Hemostatic abnormalities in patients with Ehlersâ€“Danlos syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 2425-2431.	3.8	27
219	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
220	Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes. Journal of Thrombosis and Haemostasis, 2018, 16, 2432-2441.	3.8	17
221	Risk factors for inhibitor development in severe hemophilia A. Thrombosis Research, 2018, 168, 20-27.	1.7	67
222	Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. Thrombosis Research, 2018, 169, 76-81.	1.7	4
223	Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation. Haemophilia, 2018, 24, e263-e266.	2.1	2
224	Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. British Journal of Clinical Pharmacology, 2018, 84, 2010-2019.	2.4	30
225	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
226	Choices of factor <scp>VIII</scp> products in previously untreated patients with haemophilia A: A global survey. Haemophilia, 2018, 24, e266-e268.	2.1	0
227	An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASSâ€VWF study. Journal of Thrombosis and Haemostasis, 2018, 16, 1604-1613.	3.8	7
228	Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register. European Journal of Internal Medicine, 2018, 56, 11-18.	2.2	19
229	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	1.4	2
230	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	1.4	3
231	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	1.4	3
232	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	1.4	3
233	How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Polish Archives of Internal Medicine, 2018, 128, 379-385.	0.4	17
234	High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfusion, 2018, 16, 215-220.	0.4	12

#	Article	IF	Citations
235	Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 86-89.	0.6	7
236	Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia â€" A in the Sippet Cohort Study. Blood, 2018, 132, 384-384.	1.4	0
237	Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology. Blood, 2018, 132, 222-222.	1.4	0
238	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	1.4	0
239	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, 2018, 132, 2464-2464.	1.4	0
240	Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency. Blood, 2018, 132, 2501-2501.	1.4	0
241	Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency â€" a Phase 3 Study. Blood, 2018, 132, 2502-2502.	1.4	0
242	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	1.4	2
243	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood, 2018, 132, 3781-3781.	1.4	0
244	Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report. Blood Transfusion, 2018, 16, 326-328.	0.4	0
245	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver International, 2017, 37, 1295-1303.	3.9	18
246	Molecular diagnosis of von Willebrand disease. Haemophilia, 2017, 23, 188-197.	2.1	32
247	Incidence of lowâ€titre factor VIII inhibitors in patients with haemophilia A: metaâ€analysis of observational studies. Haemophilia, 2017, 23, e87-e92.	2.1	5
248	Kreuth <scp>IV</scp>: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	2.1	15
249	Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 350-358.	1.3	6
250	Reply to the letter by Iorio. Haemophilia, 2017, 23, e248-e249.	2.1	3
251	Pregnancy outcome after a first episode of cerebral vein thrombosis: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 1526-1526.	3.8	2
252	Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2017, 15, 1448-1452.	3.8	94

#	Article	IF	Citations
253	Exploring the global landscape of genetic variation in coagulation factor XI deficiency. Blood, 2017, 130, e1-e6.	1.4	41
254	Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. Blood, 2017, 130, 666-676.	1.4	22
255	Involvement of the IgEâ€basophil system and mild complement activation in haemophilia B with antiâ€factor IX neutralizing antibodies and anaphylaxis. Haemophilia, 2017, 23, e348-e353.	2.1	8
256	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie SocietÃ Italiana di Medicina) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.7	9
257	SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361.	2.1	27
258	Efficacy and safety of a <scp>VWF</scp>/<scp>FVIII</scp> concentrate (wilate^{Â®}) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia, 2017, 23, 264-272.	2.1	29
259	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250.	1.4	41
260	New findings on inhibitor development: from registries to clinical studies. Haemophilia, 2017, 23, 4-13.	2.1	24
261	Inhibitor development in haemophilia. Haemophilia, 2017, 23, 3-3.	2.1	11
262	Minimal factorÂXIII activity level to prevent major spontaneous bleeds: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 2280-2282.	3.8	2
263	Minimal factor XIII activity level to prevent major spontaneous bleeds. Journal of Thrombosis and Haemostasis, 2017, 15, 1728-1736.	3.8	34
264	Appropriateness of antiplatelet therapy for primary and secondary cardioâ€•and cerebrovascular prevention in acutely hospitalized older people. British Journal of Clinical Pharmacology, 2017, 83, 2528-2540.	2.4	17
265	Minimal dataset for postâ€registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1878-1881.	3.8	11
266	Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PROâ€RBDD project laboratories. International Journal of Laboratory Hematology, 2017, 39, 653-662.	1.3	13
267	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759.	1.4	44
268	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine, 2017, 56, 298-307.	2.3	22
269	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	3.8	362
270	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Archives of Gerontology and Geriatrics, 2017, 69, 21-30.	3.0	17

#	Article	IF	Citations
271	ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. European Journal of Internal Medicine, 2017, 39, 79-83.	2.2	17
272	9 BIC International Conference: Rome (Italy), 15-17 September 2017. Blood Transfusion, 2017, 15, s475-s518.	0.4	0
273	Key insights to understand the immunogenicity of FVIII products. Thrombosis and Haemostasis, 2016, 116, S2-S9.	3.4	10
274	The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2016, 115, 51-62.	3.4	14
275	Thrombotic microangiopathy without renal involvement: two novel mutations in complementâ€regulator genes. Journal of Thrombosis and Haemostasis, 2016, 14, 340-345.	3.8	6
276	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. Journal of the American Heart Association, 2016, 5, .	3.7	43
277	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	2.1	11
278	The thrombin generation assay distinguishes inhibitor from nonâ€inhibitor patients with severe haemophilia A. Haemophilia, 2016, 22, e286-91.	2.1	7
279	Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway. Journal of Thrombosis and Haemostasis, 2016, 14, 1603-1614.	3.8	27
280	Plasma factor XIII level variations during menstrual cycle. Blood Coagulation and Fibrinolysis, 2016, 27, 786-790.	1.0	1
281	Pregnancy loss and risk of ischaemic stroke and myocardial infarction. British Journal of Haematology, 2016, 174, 302-309.	2.5	31
282	Baseline factor <scp>VIII</scp> plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia, 2016, 22, 564-569.	2.1	4
283	Treatment of rare factor deficiencies in 2016. Hematology American Society of Hematology Education Program, 2016, 2016, 663-669.	2.5	53
284	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw188.	3.6	41
285	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thrombosis Research, 2016, 141, 153-157.	1.7	11
286	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	27.0	414
287	Increased plasma levels of Von Willebrand factor (VWF) and Factor VIII (FVIII) during acute bacterial infection drive a pro-hemostatic imbalance and herald severe outcome in cirrhosis. Digestive and Liver Disease, 2016, 48, e13.	0.9	0
288	Advances in the treatment of bleeding disorders. Journal of Thrombosis and Haemostasis, 2016, 14, 2095-2106.	3.8	66

#	Article	IF	Citations
289	Pregnancy outcome after a first episode of cerebral vein thrombosis. Journal of Thrombosis and Haemostasis, 2016, 14, 2386-2393.	3.8	15
290	Genomic approaches to bleeding disorders. Haemophilia, 2016, 22, 42-45.	2.1	5
291	A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect. Molecular Genetics & Genomic Medicine, 2016, 4, 152-159.	1.2	9
292	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Digestive and Liver Disease, 2016, 48, 1208-1213.	0.9	20
293	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1668-1672.	3.8	6
294	Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion. Thrombosis Research, 2016, 147, 16-23.	1.7	5
295	Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood, 2016, 127, 2924-2933.	1.4	29
296	Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thrombosis Research, 2016, 148, 128-134.	1.7	22
297	Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2016, 14, 2356-2367.	3.8	10
298	von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients. Haemophilia, 2016, 22, e502-e511.	2.1	6
299	Efficacy, safety and pharmacokinetics of a new highâ€purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia, 2016, 22, 419-425.	2.1	25
300	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. Clinical Research in Cardiology, 2016, 105, 912-920.	3.3	63
301	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 2497-2498.	27.0	35
302	A critical appraisal of oneâ€stage and chromogenic assays of factor VIII activity. Journal of Thrombosis and Haemostasis, 2016, 14, 248-261.	3.8	127
303	Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia, 2016, 22, e292-300.	2.1	9
304	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. International Journal of Hematology, 2016, 103, 165-172.	1.6	13
305	The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet, The, 2016, 388, 187-197.	13.7	331
306	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 511-522.	27.0	480

#	Article	IF	Citations
307	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
308	Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke. JAMA Internal Medicine, 2016, 176, 134.	5.1	14
309	Back pain: An old cause in a young adult. European Journal of Internal Medicine, 2016, 28, e1-e2.	2.2	0
310	Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0151347.	2.5	9
311	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0165665.	2.5	7
312	Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency. Blood, 2016, 128, 1404-1404.	1.4	0
313	Natural History of Patients Affected with Thrombotic Thrombocytopenic Purpura: Milan TTP Registry. Blood, 2016, 128, 3731-3731.	1.4	1
314	Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis. Blood, 2016, 128, 325-325.	1.4	1
315	Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis. Blood, 2016, 128, 330-330.	1.4	0
316	Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 5566-5566.	1.4	0
317	Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study). Blood, 2016, 128, 207-207.	1.4	0
318	Factors Associated with Depressive Symptoms in Young Adults with Coronary Artery Disease: Tehran Heart Center's Premature Coronary Atherosclerosis Cohort (THC-PAC) Study. Iranian Journal of Psychiatry, 2016, 11, 214-223.	0.7	5
319	Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. Acta Medica Iranica, 2016, 54, 261-9.	0.8	2
320	Assessment of Clotting Factor Concentratesâ€"Pivotal Studies and Long-Term Requirements. Seminars in Thrombosis and Hemostasis, 2015, 41, 855-859.	2.7	5
321	Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 876-879.	3.8	7
322	Rare bleeding disorders: diagnosis and treatment. Blood, 2015, 125, 2052-2061.	1.4	244
323	A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica, 2015, 100, e87-e89.	3.5	4
324	Longâ€term prophylaxis in severe factor <scp>VII</scp> deficiency. Haemophilia, 2015, 21, 812-819.	2.1	16

#	Article	IF	Citations
325	Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa) Tj ETQq1 1 0.784314 rgBT /Ov Haemostasis, 2015, 13, 1459-1467.	3.8	30
326	Plasma ADAMTSâ€13 levels and the risk of myocardial infarction: an individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1396-1404.	3.8	52
327	Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. Journal of Thrombosis and Haemostasis, 2015, 13, 1806-1814.	3.8	11
328	Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 2015, 114, 670-675.	3.4	14
329	Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thrombosis and Haemostasis, 2015, 113, 567-576.	3.4	33
330	Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency. European Journal of Clinical Investigation, 2015, 45, 1087-1091.	3.4	7
331	Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review. PLoS ONE, 2015, 10, e0133523.	2.5	49
332	Procoagulatory State in Inflammatory Bowel Diseases Is Promoted by Impaired Intestinal Barrier Function. Gastroenterology Research and Practice, 2015, 2015, 1-10.	1.5	20
333	How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters. Thrombosis Research, 2015, 135, 1186-1190.	1.7	38
334	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clinical Chemistry and Laboratory Medicine, 2015, 53, 265-73.	2.3	15
335	Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 2015, 113, 968-975.	3.4	103
336	Plateletâ€dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 1345-1350.	3.8	119
337	Mediterranean spotted fever and hearing impairment: a rare complication. International Journal of Infectious Diseases, 2015, 35, 34-36.	3.3	8
338	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
339	Management of pregnancy in type 2B von Willebrand disease: case report and literature review. Haemophilia, 2015, 21, e98-103.	2.1	8
340	Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thrombosis Research, 2015, 136, 168-174.	1.7	18
341	Introduction and overview. Blood Reviews, 2015, 29, S1-S3.	5.7	0
342	Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. , 2015, , 209-221.		0

#	Article	IF	Citations
343	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine, 2015, 26, 330-337.	2.2	25
344	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.5	12
345	Research in haemophilia B â€“ approaching the request for high evidence levels in a rare disease. Haemophilia, 2015, 21, 4-20.	2.1	3
346	Treatment of Hemophilia in the Near Future. Seminars in Thrombosis and Hemostasis, 2015, 41, 838-848.	2.7	16
347	Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. Journal of Thrombosis and Haemostasis, 2015, 13, 228-236.	3.8	18
348	Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient. Journal of Clinical Apheresis, 2015, 30, 252-256.	1.3	5
349	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis. Blood, 2015, 126, 4680-4680.	1.4	3
350	Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Blood, 2015, 126, 5-5.	1.4	16
351	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
352	International databases open the door to improved care for rare bleeding disorders. The Journal of Haemophilia Practice, 2015, 2, 11-12.	0.4	0
353	Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study. The Journal of Tehran Heart Center, 2015, 10, 34-42.	0.3	4
354	FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thrombosis and Haemostasis, 2014, 112, 297-303.	3.4	19
355	Genetic background and risk of postpartum haemorrhage: results from an Italian cohort of 3219 women. Haemophilia, 2014, 20, e377-83.	2.1	12
356	Measurement and prevalence of circulating ADAMTS13â€specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2014, 12, 329-336.	3.8	31
357	Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a caseâ€“control study. Orphanet Journal of Rare Diseases, 2014, 9, 193.	2.7	18
358	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. Nature Medicine, 2014, 20, 466-466.	30.7	3
359	Pediatric requirements in Europe stymie help for hemophilia. Nature Medicine, 2014, 20, 117-117.	30.7	8
360	Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. Revista Portuguesa De Pneumologia, 2014, 20, 324-335.	0.7	22

#	Article	IF	Citations
361	Orthopaedic surgery in patients with von Willebrand disease. Haemophilia, 2014, 20, 133-140.	2.1	25
362	Rare bleeding disorders â€“ bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia, 2014, 20, 71-75.	2.1	67
363	Changes in factor <scp>XIII</scp> level during pregnancy. Haemophilia, 2014, 20, e144-8.	2.1	33
364	A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome. Thrombosis Research, 2014, 134, 1316-1322.	1.7	6
365	Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe ?. Haemophilia, 2014, 20, 455-458.	2.1	1
366	A twoâ€•centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia, 2014, 20, 147-153.	2.1	39
367	Integrated postural analysis in children with haemophilia. Haemophilia, 2014, 20, 263-267.	2.1	12
368	Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 <scp>AICE</scp> survey. Haemophilia, 2014, 20, e128-35.	2.1	15
369	Congenital factor <scp>XIII</scp> deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia, 2014, 20, 568-574.	2.1	11
370	Assaying <scp>FVIII</scp> activity: one method is not enough, and never was. Haemophilia, 2014, 20, 301-303.	2.1	15
371	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
372	Joint <scp>WFH</scp>â€•<scp>ISTH</scp> session: issues in clinical trial design. Haemophilia, 2014, 20, 137-144.	2.1	7
373	Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion, 2014, 54, 1756-1768.	1.6	167
374	A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thrombosis Research, 2014, 133, 481-487.	1.7	8
375	Management of orthopaedic surgery in rare bleeding disorders. Haemophilia, 2014, 20, 693-701.	2.1	16
376	Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia, 2014, 20, e243-50.	2.1	19
377	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	2.2	1
378	Comparison of Thrombin Generation Assay With Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With Rare Bleeding Disorders. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 637-644.	1.7	20

#	Article	IF	Citations
379	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
380	Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Experimental Hematology and Oncology, 2014, 3, 15.	5.0	2
381	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	3.7	149
382	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. Thrombosis Research, 2014, 133, 1130-1134.	1.7	9
383	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	1.4	123
384	Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial. Blood, 2014, 124, 229-229.	1.4	11
385	Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Prelimary Results of the PRO-RBDD Project. Blood, 2014, 124, 2838-2838.	1.4	3
386	Patients with Mild Hemophilia a with Discrepant FVIII Assays: Thrombin Generation and Bleeding Phenotype. Blood, 2014, 124, 2844-2844.	1.4	1
387	Clots from FXI-Deficient Patients Display a Reduced Fibrinolytic Resistance. Blood, 2014, 124, 4219-4219.	1.4	1
388	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52
389	The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2014, 124, 1467-1467.	1.4	0
390	Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency. Blood, 2014, 124, 2817-2817.	1.4	1
391	The European Haemophilia Network (EUHANET). Blood Transfusion, 2014, 12 Suppl 3, s515-8.	0.4	11
392	Global coagulation in myeloproliferative neoplasms. Annals of Hematology, 2013, 92, 1633-1639.	1.8	26
393	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Internal and Emergency Medicine, 2013, 8, 509-520.	2.0	23
394	Genetic sequence analysis of inherited bleeding diseases. Blood, 2013, 122, 3423-3431.	1.4	48
395	Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. Thrombosis Research, 2013, 132, e152-e157.	1.7	29
396	Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thrombosis Research, 2013, 132, 116-122.	1.7	8

#	Article	IF	Citations
397	Treatment of chronic hepatitis C with pegylated interferonâ€Ì± inÂa patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfusion Medicine, 2013, 23, 66-68.	1.1	2
398	The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Reviews, 2013, 27, 71-76.	5.7	17
399	Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. European Journal of Internal Medicine, 2013, 24, 80-82.	2.2	13
400	Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. Blood Cells, Molecules, and Diseases, 2013, 50, 59-60.	1.4	4
401	Future of coagulation factor replacement therapy. Journal of Thrombosis and Haemostasis, 2013, 11, 84-98.	3.8	61
402	Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thrombosis Research, 2013, 132, 256-262.	1.7	24
403	Nextâ€generation sequencing study finds an excess of rare, coding singleâ€nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2013, 11, 1228-1239.	3.8	52
404	Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. JAMA Surgery, 2013, 148, 755.	4.3	140
405	Rare Bleeding Disorders: Worldwide Efforts for Classification, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2013, 39, 579-584.	2.7	58
406	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. Pediatrics, 2013, 132, e1435-e1439.	2.1	33
407	Preoperative Hematocrit Concentration and the Risk of Stroke in Patients Undergoing Isolated Coronary-Artery Bypass Grafting. Anemia, 2013, 2013, 1-7.	1.7	7
408	The typeÂ2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress. Journal of Thrombosis and Haemostasis, 2013, 11, 1688-1698.	3.8	15
409	ADAMTS13 content in plasmaâ€derived factor VIII/von Willebrand factor concentrates. American Journal of Hematology, 2013, 88, 895-898.	4.1	36
410	A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia, 2013, 19, 338-342.	2.1	61
411	Pregnancy complications and obstetric care in women with inherited bleeding disorders. Haemophilia, 2013, 19, 1-10.	2.1	173
412	A synonymous (c.3390C>T) or a spliceâ€site (c.3380â€2A>G) mutation causes exonÂ26 skipping in four patients with von Willebrand disease (2A/IIE). Journal of Thrombosis and Haemostasis, 2013, 11, 1251-1259.	3.8	15
413	Raised haematocrit concentration and the risk of death and vascular complications after major surgery. British Journal of Surgery, 2013, 100, 1030-1036.	0.3	13
414	Postoperative Outcomes After Laparoscopic Splenectomy Compared With Open Splenectomy. Annals of Surgery, 2013, 257, 1116-1123.	4.2	29

#	Article	IF	Citations
415	Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thrombosis and Haemostasis, 2013, 109, 488-496.	3.4	39
416	Is Hemophilia B Less Severe Than Hemophilia A? Results Of Global Coagulation Assays. Blood, 2013, 122, 2352-2352.	1.4	4
417	Prevalence of Disease and Relationships between Laboratory Phenotype and Bleeding Severity in Platelet Primary Secretion Defects. PLoS ONE, 2013, 8, e60396.	2.5	17
418	Diagnostic relevance of ADAMTS13 activity: Evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 466-474.	0.2	0
419	Rare Genetic Variants Of The Protein-Coding Area Of The Genome and The Risk Of Inhibitor Development: An Exome-Sequencing Study Of 28 Patients With Severe Hemophilia A. Blood, 2013, 122, 571-571.	1.4	0
420	Thrombin Generation Assay During Orthopaedic Surgery In Hemophilia A With and Without Inhibitors: Results From In Vivo Studies. Blood, 2013, 122, 3591-3591.	1.4	6
421	Plasma FXIII LEVEL Variations During Menstrual CYCLE. Blood, 2013, 122, 4777-4777.	1.4	0
422	Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. Blood Transfusion, 2013, 11, 241-4.	0.4	5
423	Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 100-103.	1.7	12
424	Prothrombin Mutation Conveying Antithrombin Resistance. New England Journal of Medicine, 2012, 367, 1069-1070.	27.0	6
425	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	107
426	Pediatric stroke and ADAMTS genes. Blood, 2012, 120, 5097-5098.	1.4	1
427	ADAMTSâ€13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 1556-1565.	3.8	74
428	Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. Journal of Thrombosis and Haemostasis, 2012, 10, 1938-1943.	3.8	129
429	Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2012, 34, 416-418.	2.1	2
430	The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 2322-2325.	1.5	37
431	Epidemiology and treatment of congenital fibrinogen deficiency. Thrombosis Research, 2012, 130, S7-S11.	1.7	93
432	Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. American Journal of Hematology, 2012, 87, 870-874.	4.1	10

#	Article	IF	Citations
433	Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia, 2012, 18, 34-38.	2.1	30
434	Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency. Haemophilia, 2012, 18, 205-210.	2.1	4
435	Efficacy of prophylaxis and genotypeâ€phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia, 2012, 18, 211-215.	2.1	34
436	Foreword. Haemophilia, 2012, 18, 1-1.	2.1	0
437	Management of bleeding disorders in adults. Haemophilia, 2012, 18, 24-36.	2.1	8
438	Rare bleeding disorders. Haemophilia, 2012, 18, 148-153.	2.1	58
439	Polymorphic mi<scp>RNA</scp>â€mediated gene contribution to inhibitor development in haemophilia A. Haemophilia, 2012, 18, 1003-1007.	2.1	9
440	von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 728-730.	3.8	6
441	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 2012, 10, 615-621.	3.8	362
442	Measurement of antiâ€ADAMTS13 neutralizing autoantibodies: a comparison between CBA and FRET assays. Journal of Thrombosis and Haemostasis, 2012, 10, 1439-1442.	3.8	16
443	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 2012, 10, 1451-1453.	3.8	24
444	Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 2012, 158, 323-335.	2.5	700
445	Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes. BMC Medical Genomics, 2012, 5, 7.	1.5	32
446	Initial experience from a doubleâ€blind, placeboâ€controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2012, 87, 430-432.	4.1	71
447	Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.. Blood, 2012, 120, 2088-2088.	1.4	2
448	Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. , 2012, , 131-141.		0
449	Complications of Pregnancy in Women with Thrombotic Thrombocytopenic Purpura. Blood, 2012, 120, 3322-3322.	1.4	0
450	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. Blood, 2012, 120, 3383-3383.	1.4	1

#	Article	IF	Citations
451	Rare Coding Single Nucleotide Variants of ADAMTS13 Are Associated with Deep Vein Thrombosis in a Next-Generation Sequencing Association Study. Blood, 2012, 120, 107-107.	1.4	0
452	Factor VIII inhibitor and source of replacement therapy. Blood Transfusion, 2012, 10, 112-3.	0.4	1
453	Influence of 9p21.3 Genetic Variants on Clinical and Angiographic Outcomes in Early-Onset Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 426-434.	2.8	66
454	Management of pregnancy and delivery in women with inherited bleeding disorders. Seminars in Fetal and Neonatal Medicine, 2011, 16, 311-317.	2.3	40
455	Knowledge and Therapeutic Gaps. American Journal of Preventive Medicine, 2011, 41, S324-S331.	3.0	13
456	Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 124-134.	1.1	108
457	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
458	B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thrombosis Research, 2011, 128, 590-592.	1.7	5
459	Post-partum hemorrhage in women with rare bleeding disorders. Thrombosis Research, 2011, 127, S116-S119.	1.7	12
460	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis, 2011, 214, 397-403.	0.8	47
461	Addressing the complexity of cardiovascular disease by design. Lancet, The, 2011, 377, 356-358.	13.7	11
462	Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thrombosis and Haemostasis, 2011, 105, 381-385.	3.4	27
463	Novel aspects of factor XIII deficiency. Current Opinion in Hematology, 2011, 18, 366-372.	2.5	67
464	Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagulation and Fibrinolysis, 2011, 22, 396-401.	1.0	16
465	Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia, 2011, 17, 252-256.	2.1	17
466	The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. Haemophilia, 2011, 17, 820-821.	2.1	2
467	Non-invasive tool for foetal sex determination in early gestational age. Haemophilia, 2011, 17, 952-956.	2.1	13
468	Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. Haemophilia, 2011, 17, 14-17.	2.1	18

#	Article	IF	Citations
469	Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTSâ€13. Journal of Thrombosis and Haemostasis, 2011, 9, 1620-1627.	3.8	17
470	Fibrinogen replacement therapy for congenital fibrinogen deficiency. Journal of Thrombosis and Haemostasis, 2011, 9, 1687-1704.	3.8	124
471	Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. Journal of Thrombosis and Haemostasis, 2011, 9, 1744-1751.	3.8	22
472	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.4	1,685
473	Gynecological and obstetrical manifestations of inherited bleeding disorders in women. Journal of Thrombosis and Haemostasis, 2011, 9, 236-245.	3.8	64
474	Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population. Thrombosis and Haemostasis, 2011, 106, 855-864.	3.4	26
475	Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease. PLoS Genetics, 2011, 7, e1002260.	3.5	203
476	Abdominal Aortic Aneurysm Is Associated with a Variant in Low-Density Lipoprotein Receptor-Related Protein 1. American Journal of Human Genetics, 2011, 89, 619-627.	6.2	185
477	Role of von Willebrand factor in the haemostasis. Blood Transfusion, 2011, 9 Suppl 2, s3-8.	0.4	89
478	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. Blood, 2011, 118, 2219-2219.	1.4	0
479	Identification of DEEP Vein Thrombosis GENETIC RISK Variants by NEXT GENERATION Sequencing of Hemostatic Genes. Blood, 2011, 118, 710-710.	1.4	0
480	Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia, 2010, 16, 469-473.	2.1	20
481	Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica, 2010, 95, 1444-1447.	3.5	19
482	Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI pre-mRNA. Blood, 2010, 115, 2065-2072.	1.4	23
483	Response: Further thoughts on the â€œphantomâ€Î”6/7 FXI isoform. Blood, 2010, 116, 1186-1187.	1.4	3
484	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radical Biology and Medicine, 2010, 48, 446-456.	2.9	56
485	ADAMTS13mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Human Mutation, 2010, 31, 11-19.	2.5	165
486	Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2010, 8, 416-418.	3.8	0

#	Article	IF	Citations
487	ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 631-640.	3.8	103
488	Active plateletâ€binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2010, 8, 1653-1656.	3.8	19
489	No association between chromosome 12p13 single nucleotide polymorphisms and earlyâ€onset ischemic stroke. Journal of Thrombosis and Haemostasis, 2010, 8, 1858-1860.	3.8	20
490	Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2010, 8, 2053-2062.	3.8	31
491	The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. Journal of Thrombosis and Haemostasis, 2010, 8, 2116-2121.	3.8	50
492	Factor XIII â€“ an under diagnosed deficiency â€“ are we using the right assays?. Journal of Thrombosis and Haemostasis, 2010, 8, 2478-2482.	3.8	65
493	Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. British Journal of Haematology, 2010, 151, 488-494.	2.5	46
494	The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sanguinis, 2010, 99, 232-238.	1.5	33
495	Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. Journal of Lipid Research, 2010, 51, 3342-3349.	4.2	41
496	Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. Thrombosis and Haemostasis, 2010, 104, 231-242.	3.4	35
497	A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2010, 116, 726-726.	1.4	4
498	ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2010, 116, 2532-2532.	1.4	0
499	Genome-wide association studies in myocardial infarction and coronary artery disease. The Journal of Tehran Heart Center, 2010, 5, 116-21.	0.3	1
500	The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 289-293.	3.5	22
501	Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency. Thrombosis and Haemostasis, 2009, 102, 603-606.	3.4	3
502	Association and Functional Analyses of MEF2A as a Susceptibility Gene for Premature Myocardial Infarction and Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2009, 2, 165-172.	5.1	32
503	Rare Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2009, 35, 345-347.	2.7	17
504	Factor V Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 382-389.	2.7	114

#	Article	IF	Citations
505	Factor X Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 407-415.	2.7	125
506	Introduction: Rare Bleeding Disorders: General Aspects of Clinical Features, Diagnosis, and Management. Seminars in Thrombosis and Hemostasis, 2009, 35, 349-355.	2.7	123
507	Autoimmune hemophilia at rescue. Haematologica, 2009, 94, 459-461.	3.5	9
508	Combined Factor V and Factor VIII Deficiency. Seminars in Thrombosis and Hemostasis, 2009, 35, 390-399.	2.7	49
509	Genetic Architecture of Coronary Artery Disease in the Genome-Wide Era: Implications for the Emerging â€œGolden Dozenâ€•Loci. Seminars in Thrombosis and Hemostasis, 2009, 35, 671-682.	2.7	36
510	Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. American Journal of Obstetrics and Gynecology, 2009, 201, 12.e1-12.e8.	1.3	130
511	Factor XI deficiency in Southern Iran: identification of a novel missense mutation. Annals of Hematology, 2009, 88, 359-363.	1.8	7
512	Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia, 2009, 15, 1291-1299.	2.1	43
513	New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nature Genetics, 2009, 41, 280-282.	21.4	440
514	Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nature Genetics, 2009, 41, 334-341.	21.4	990
515	Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. Journal of Thrombosis and Haemostasis, 2009, 7, 774-779.	3.8	27
516	Pharmacokinetics and safety of fibrinogen concentrate. Journal of Thrombosis and Haemostasis, 2009, 7, 2064-2069.	3.8	100
517	Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thrombosis Research, 2009, 124, S9-S11.	1.7	29
518	Fibrinogen concentrates. Clinical Advances in Hematology and Oncology, 2009, 7, 788-90.	0.3	5
519	Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation. Pediatric Blood and Cancer, 2008, 50, 113-114.	1.5	16
520	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 2008, 6, 1450-1452.	3.8	8
521	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). Journal of Thrombosis and Haemostasis, 2008, 6, 1534-1541.	3.8	57
522	Genetic aspects and research development in haemostasis. Haemophilia, 2008, 14, 113-118.	2.1	3

#	Article	IF	Citations
523	Rare bleeding disorders. Haemophilia, 2008, 14, 202-210.	2.1	82
524	Combined FV and FVIII deficiency. Haemophilia, 2008, 14, 1201-1208.	2.1	54
525	The Genetic Basis of Coronary Artery Disease: From Candidate Genes to Whole Genome Analysis. Trends in Cardiovascular Medicine, 2008, 18, 157-162.	4.9	28
526	Mechanistic Studies on ADAMTS13 Catalysis. Biophysical Journal, 2008, 95, 2450-2461.	0.5	22
527	Congenital hypofibrinogenemia: Characterization of two missense mutations affecting fibrinogen assembly and secretion. Blood Cells, Molecules, and Diseases, 2008, 41, 292-297.	1.4	15
528	Thrombophilia Screening: Little Role for the JAK2V617F Mutation. Mayo Clinic Proceedings, 2008, 83, 398-399.	3.0	5
529	Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. Haematologica, 2008, 93, 1505-1513.	3.5	23
530	Effects ofCYP2C9andVKORC1on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics, 2008, 9, 1237-1250.	1.3	38
531	Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica, 2008, 93, 934-938.	3.5	47
532	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood, 2008, 111, 5592-5600.	1.4	63
533	ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 2008, 93, 232-239.	3.5	250
534	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica, 2008, 93, 722-728.	3.5	95
535	Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagulation and Fibrinolysis, 2008, 19, 777-783.	1.0	71
536	Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. Haematologica, 2008, 93, 1678-1685.	3.5	20
537	National and international registries of rare bleeding disorders. Blood Transfusion, 2008, 6 Suppl 2, s45-8.	0.4	17
538	Genotyp-Phenotype Correlation in Congenital ADAMTS13 Deficient Patients. Blood, 2008, 112, 273-273.	1.4	0
539	Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets, 2007, 18, 409-413.	2.3	13
540	TTP and ADAMTS13: When Is Testing Appropriate?. Hematology American Society of Hematology Education Program, 2007, 2007, 121-126.	2.5	54

#	Article	IF	Citations
541	Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. Blood Coagulation and Fibrinolysis, 2007, 18, 81-84.	1.0	12
542	Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 781-787.	3.8	10
543	Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. Thrombosis and Haemostasis, 2007, 97, 546-551.	3.4	21
544	Force fluctuations during the Maximum Isometric Voluntary Contraction of the quadriceps femoris in haemophilic patients. Haemophilia, 2007, 13, 65-70.	2.1	94
545	Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India. Haemophilia, 2007, 13, 413-419.	2.1	19
546	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (p	2.1	90
547	A novel mutation of Î±2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia, 2007, 14, 071027033511002-???.	2.1	9
548	ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. British Journal of Haematology, 2007, 138, 534-540.	2.5	135
549	Antiâ€beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. Journal of Thrombosis and Haemostasis, 2007, 5, 2421-2428.	3.8	67
550	DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS. Journal of Thrombosis and Haemostasis, 2007, 5, P-T-303-P-T-303.	3.8	2
551	Thrombospondin-1 as a Modulator of ADAMTS13 Activity.. Blood, 2007, 110, 3711-3711.	1.4	0
552	Rare coagulation disorders: an emerging issue. Blood Transfusion, 2007, 5, 185-6.	0.4	0
553	Mutational screening of six afibrinogenemic patients: identification and characterization of four novel molecular defects. Thrombosis and Haemostasis, 2007, 97, 546-51.	3.4	7
554	Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood, 2006, 107, 1903-1907.	1.4	111
555	Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24 000 years ago. Blood, 2006, 107, 4666-4668.	1.4	48
556	The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood, 2006, 108, 1280-1283.	1.4	52
557	Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Journal of Thrombosis and Haemostasis, 2006, 4, 701-702.	3.8	4
558	Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. Journal of Thrombosis and Haemostasis, 2006, 4, 1634-1637.	3.8	122

#	Article	IF	Citations
559	The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS Journal, 2006, 273, 159-169.	4.7	30
560	Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. British Journal of Haematology, 2006, 134, 187-195.	2.5	51
561	Variants of OCTN1â€“2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 497-506.	3.7	57
562	Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia, 2006, 12, 82-89.	2.1	123
563	Rare bleeding disorders. Haemophilia, 2006, 12, 137-142.	2.1	76
564	Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Internal and Emergency Medicine, 2006, 1, 35-39.	2.0	7
565	Mechanisms of the interaction between twoADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Human Mutation, 2006, 27, 330-336.	2.5	39
566	Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF). Journal of Biological Chemistry, 2006, 281, 30400-30411.	3.4	17
567	Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura.. Blood, 2006, 108, 1060-1060.	1.4	1
568	Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms.. Blood, 2006, 108, 333-333.	1.4	0
569	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. Blood, 2006, 108, 1061-1061.	1.4	0
570	Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. Haematologica, 2006, 91, 628-33.	3.5	12
571	The role of ADAMTS13 in the new pathogenesis of TTP. Hematology, 2005, 10, 47-48.	1.5	4
572	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
573	A critical role for Gly25 in the B chain of human thrombin. Journal of Thrombosis and Haemostasis, 2005, 3, 139-145.	3.8	9
574	Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 2005, 3, 280-286.	3.8	35
575	Factor VII gene polymorphisms are not associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 2005, 3, 803-804.	3.8	7
576	Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. International Journal of Laboratory Hematology, 2005, 27, 324-327.	0.2	17

#	Article	IF	Citations
577	Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3â€² untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency. Human Mutation, 2005, 26, 455-461.	2.5	16
578	Mutations in theMCFD2 gene and a novel mutation in theLMAN1 gene in Indian families with combined deficiency of factor V and VIII. American Journal of Hematology, 2005, 79, 262-266.	4.1	24
579	Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thrombosis and Haemostasis, 2005, 93, 481-487.	3.4	218
580	Carrier Detection and Prenatal Diagnosis of Hemophilia in Developing Countries. Seminars in Thrombosis and Hemostasis, 2005, 31, 544-554.	2.7	32
581	Thrombosis in Inflammatory Bowel Diseases: Role of Inherited Thrombophilia. American Journal of Gastroenterology, 2005, 100, 2036-2041.	0.4	85
582	Performance of Clinical Laboratories for DNA Analyses to Detect Thrombophilia Mutations. Clinical Chemistry, 2005, 51, 1310-1311.	3.2	13
583	Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13. Journal of Biological Chemistry, 2005, 280, 23295-23302.	3.4	43
584	Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertility and Sterility, 2005, 84, 1338-1344.	1.0	53
585	Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertility and Sterility, 2005, 84, 1345-1351.	1.0	81
586	Requirements for research investigations to clarify the relationships and management of menstrual abnormalities in women with hemostatic disorders. Fertility and Sterility, 2005, 84, 1360-1365.	1.0	9
587	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
588	Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. Haematologica, 2005, 90, 418-9.	3.5	3
589	Missense or splicing mutation? The case of a fibrinogen BÎ²-chain mutation causing severe hypofibrinogenemia. Blood, 2004, 103, 3051-3054.	1.4	21
590	A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human Î±-Thrombin. Journal of Biological Chemistry, 2004, 279, 13035-13043.	3.4	21
591	von Willebrand factor cleaving protease (ADAMTSâ€13) and ADAMTSâ€13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 2004, 127, 433-439.	2.5	142
592	The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. British Journal of Haematology, 2004, 127, 576-584.	2.5	5
593	Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Haemophilia, 2004, 10, 367-369.	2.1	25
594	Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen AÎ±-chain gene. European Journal of Human Genetics, 2004, 12, 891-898.	2.8	32

#	Article	IF	Citations
595	A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency. American Journal of Hematology, 2004, 77, 90-91.	4.1	26
596	Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. American Journal of Hematology, 2004, 77, 198-199.	4.1	94
597	Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. Human Mutation, 2004, 23, 98-98.	2.5	45
598	CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clinical Pharmacology and Therapeutics, 2004, 75, 198-203.	4.7	90
599	Recessively inherited coagulation disorders. Blood, 2004, 104, 1243-1252.	1.4	479
600	In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.. Blood, 2004, 104, 514-514.	1.4	2
601	Molecular characterization of a factor VII deficient patient supports the importance of the second epidermal growth factor-like domain. Haematologica, 2004, 89, 979-84.	3.5	4
602	Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica, 2004, 89, 1332-40.	3.5	17
603	Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain. Journal of Thrombosis and Haemostasis, 2003, 1, 1237-1244.	3.8	23
604	Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. Journal of Thrombosis and Haemostasis, 2003, 1, 1852-1853.	3.8	101
605	Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. Journal of Thrombosis and Haemostasis, 2003, 1, 2252-2253.	3.8	12
606	Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency?misdiagnosis by direct sequence analysis using a PCR product. Prenatal Diagnosis, 2003, 23, 731-734.	2.3	15
607	Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells, Molecules, and Diseases, 2003, 30, 264-270.	1.4	95
608	Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bî²-chain gene. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2003, 1639, 87-94.	3.8	24
609	No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age. Circulation, 2003, 107, 1117-1122.	1.6	191
610	Risk of Myocardial Infarction and Polymorphisms in Candidate Genes. New England Journal of Medicine, 2003, 348, 1176-1177.	27.0	2
611	Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood, 2003, 101, 173-177.	1.4	41
612	Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood, 2003, 102, 3210-3216.	1.4	38

#	Article	IF	Citations
613	Vagaries of genetic association studies in myocardial infarction. Blood, 2003, 102, 1558-1560.	1.4	2
614	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica, 2003, 88, 454-8.	3.5	37
615	Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood, 2002, 100, 1347-1353.	1.4	28
616	Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen BÎ²-chain gene causing activation of cryptic splice sites. Blood, 2002, 100, 4478-4484.	1.4	37
617	Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis. Thrombosis and Haemostasis, 2002, 87, 342-343.	3.4	46
618	Allele Frequency of CYP2C9 Gene Polymorphisms in Iran. Thrombosis and Haemostasis, 2002, 88, 874-875.	3.4	16
619	The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding. Thrombosis and Haemostasis, 2002, 88, 576-582.	3.4	261
620	Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. Thrombosis and Haemostasis, 2002, 88, 750-755.	3.4	4
621	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations â€“ A Cause for Concern. Thrombosis and Haemostasis, 2002, 88, 690-691.	3.4	41
622	Rare coagulation deficiencies. Haemophilia, 2002, 8, 308-321.	2.1	215
623	Gene mutations and threeâ€dimensional structural analysis in 13 families with severe factor X deficiency. British Journal of Haematology, 2002, 117, 685-692.	2.5	61
624	Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thrombosis and Haemostasis, 2002, 87, 342-3.	3.4	27
625	Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica, 2002, 87, 512-4.	3.5	40
626	Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. Haematologica, 2002, 87, 855-9.	3.5	23
627	The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thrombosis and Haemostasis, 2002, 88, 576-82.	3.4	60
628	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern. Thrombosis and Haemostasis, 2002, 88, 690-1.	3.4	6
629	Two naturally occurring mutations on FVII gene (S363I-W364C) altering intrinsic catalytic activity. Thrombosis and Haemostasis, 2002, 88, 750-5.	3.4	0
630	Allele frequency of CYP2C9 gene polymorphisms in Iran. Thrombosis and Haemostasis, 2002, 88, 874-5.	3.4	5

#	Article	IF	Citations
631	Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood, 2001, 97, 960-965.	1.4	15
632	Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen AÎ±-chain gene are not associated with the decay of the mutant mRNAs. Blood, 2001, 98, 3685-3692.	1.4	68
633	AUTOSOMAL RECESSIVE DEFICIENCIES OF COAGULATION FACTORS. Reviews in Clinical and Experimental Hematology, 2001, 5, 369-388.	0.1	28
634	A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. British Journal of Haematology, 2000, 108, 247-253.	2.5	17
635	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	91
636	Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease. Thrombosis and Haemostasis, 2000, 84, 536-540.	3.4	61
637	Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII. Thrombosis and Haemostasis, 2000, 84, 635-637.	3.4	12
638	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	152
639	Molecular Characterisation and Three-Dimensional Structural Analysis of Mutations in 21 Unrelated Families with Inherited Factor VII Deficiency. Thrombosis and Haemostasis, 2000, 84, 250-257.	3.4	67
640	Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thrombosis and Haemostasis, 2000, 84, 250-7.	3.4	13
641	Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thrombosis and Haemostasis, 2000, 84, 536-40.	3.4	15
642	Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. Thrombosis and Haemostasis, 2000, 84, 635-7.	3.4	3
643	Rare Coagulation Disorders. Thrombosis and Haemostasis, 1999, 82, 1207-1214.	3.4	180
644	Characterization of Two Naturally Occurring Mutations in the Second Epidermal Growth Factor-Like Domain of Factor VII. Blood, 1999, 93, 1237-1244.	1.4	30
645	Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. British Journal of Haematology, 1999, 107, 204-206.	2.5	233
646	Molecular Analysis of the ERGIC-53 Gene in 35 Families With Combined Factor V-Factor VIII Deficiency. Blood, 1999, 93, 2253-2260.	1.4	83
647	Characterization of Two Naturally Occurring Mutations in the Second Epidermal Growth Factor-Like Domain of Factor VII. Blood, 1999, 93, 1237-1244.	1.4	0
648	Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood, 1999, 93, 1237-44.	1.4	5

#	Article	IF	Citations
649	Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood, 1999, 93, 2253-60.	1.4	43
650	Rare coagulation disorders. Thrombosis and Haemostasis, 1999, 82, 1207-14.	3.4	36
651	Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. British Journal of Haematology, 1998, 100, 773-776.	2.5	84
652	Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. British Journal of Haematology, 1998, 102, 626-628.	2.5	121
653	Symptoms of inherited factor V deficiency in 35 Iranian patients. British Journal of Haematology, 1998, 103, 1067-1069.	2.5	109
654	Gene Polymorphisms Predicting High Plasma Levels of Coagulation and Fibrinolysis Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 755-759.	2.4	103
655	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia, 1997, 3, 242-246.	2.1	92
656	Autoimmune Protein S Deficiency and Deep Vein Thrombosis after Chickenpox. Thrombosis and Haemostasis, 1996, 75, 212-213.	3.4	9
657	Frequency of Factor V Arg506 Gin in Italians. Thrombosis and Haemostasis, 1996, 75, 694-694.	3.4	4
658	Autoimmune protein S deficiency and deep vein thrombosis after chickenpox. Thrombosis and Haemostasis, 1996, 75, 212-3.	3.4	3
659	Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. Thrombosis and Haemostasis, 1996, 75, 701-2.	3.4	5
660	Factor V and Combined Factor V and VIII Deficiencies. , 0, , 306-310.		1
661	Rare Bleeding Disorders. , 0, , 54-64.		0
662	Congenital Bleeding: Autosomal Recessive Disorders. , 0, , 842-858.		0
663	Thrombotic Thrombocytopenic Purpura and Haemolytic Uraemic Syndrome (Congenital and Acquired). , 0, , 876-884.		0